Efficacy and safety data on pretomanid for drug-resistant TB
OBJECTIVE: To summarise the efficacy and safety of pretomanid (Pa) based regimens in patients with drug-resistant TB (DR-TB). METHODS: We included clinical trials, operational research and observational studies reporting the efficacy and safety of Pa-based regimens in DR-TB. The duration of the trea...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
International Union Against Tuberculosis and Lung Disease (The Union)
2025-02-01
|
| Series: | IJTLD Open |
| Subjects: | |
| Online Access: | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2025/00000002/00000002/art00004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850197890201288704 |
|---|---|
| author | H.T.T. Thuy C. Padmapriyadarsini C. Chuchottaworn S. Foraida S. Hadigal A.R. Birajdar |
| author_facet | H.T.T. Thuy C. Padmapriyadarsini C. Chuchottaworn S. Foraida S. Hadigal A.R. Birajdar |
| author_sort | H.T.T. Thuy |
| collection | DOAJ |
| description | OBJECTIVE: To summarise the efficacy and safety of pretomanid (Pa) based regimens in patients with drug-resistant TB (DR-TB). METHODS: We included clinical trials, operational research and observational studies reporting the efficacy and safety of Pa-based regimens in DR-TB. The duration of the treatment was at least 24 weeks. Efficacy was reported as a favourable/unfavourable outcome and culture conversion. Safety was reported in terms of death and frequency of adverse events of special interest. RESULTS: Of the 127 articles identified, 13 were included. The proportion of favourable outcomes reported was 76−100%, and the median time to culture conversion was 4−6 weeks. Culture conversion rates ranged from 80–100% by the end of 3 months of treatment, regardless of the type of drug resistance. Treatment completion rates in the operational research studies varied between 18–93%. Safety events were not proportionate among the studies included, possibly due to the differing linezolid dosing (more frequent in the 1,200 mg dose regimen). CONCLUSION: Our review supports the use of Pa-based regimens in patients with DR-TB. The results indicate that Pa-based regimens are efficacious with tolerable safety profile in DR-TB patients. |
| format | Article |
| id | doaj-art-5d63c7a725464eb9aef4b2ab60c56a51 |
| institution | OA Journals |
| issn | 3005-7590 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | International Union Against Tuberculosis and Lung Disease (The Union) |
| record_format | Article |
| series | IJTLD Open |
| spelling | doaj-art-5d63c7a725464eb9aef4b2ab60c56a512025-08-20T02:13:01ZengInternational Union Against Tuberculosis and Lung Disease (The Union)IJTLD Open3005-75902025-02-0122738210.5588/ijtldopen.24.03604Efficacy and safety data on pretomanid for drug-resistant TBH.T.T. Thuy0C. Padmapriyadarsini1C. Chuchottaworn2S. Foraida3S. Hadigal4A.R. Birajdar5National TB Control Programme of Vietnam, National Lung Hospital, Hanoi, Vietnam;National Institute for Research in Tuberculosis, Indian Council of Medical Research, Chennai, India;Department of Medical Services, Central Chest Institute of Thailand, Nonthaburi, Thailand;TB Alliance, New York, NY, USA;Department of Medical Affairs, Viatris, India.Department of Medical Affairs, Viatris, India.OBJECTIVE: To summarise the efficacy and safety of pretomanid (Pa) based regimens in patients with drug-resistant TB (DR-TB). METHODS: We included clinical trials, operational research and observational studies reporting the efficacy and safety of Pa-based regimens in DR-TB. The duration of the treatment was at least 24 weeks. Efficacy was reported as a favourable/unfavourable outcome and culture conversion. Safety was reported in terms of death and frequency of adverse events of special interest. RESULTS: Of the 127 articles identified, 13 were included. The proportion of favourable outcomes reported was 76−100%, and the median time to culture conversion was 4−6 weeks. Culture conversion rates ranged from 80–100% by the end of 3 months of treatment, regardless of the type of drug resistance. Treatment completion rates in the operational research studies varied between 18–93%. Safety events were not proportionate among the studies included, possibly due to the differing linezolid dosing (more frequent in the 1,200 mg dose regimen). CONCLUSION: Our review supports the use of Pa-based regimens in patients with DR-TB. The results indicate that Pa-based regimens are efficacious with tolerable safety profile in DR-TB patients.https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2025/00000002/00000002/art00004tuberculosisextensively drug-resistant tuberculosispre-extensively drug-resistant tuberculosismultidrug-resistant tuberculosisadverse events |
| spellingShingle | H.T.T. Thuy C. Padmapriyadarsini C. Chuchottaworn S. Foraida S. Hadigal A.R. Birajdar Efficacy and safety data on pretomanid for drug-resistant TB IJTLD Open tuberculosis extensively drug-resistant tuberculosis pre-extensively drug-resistant tuberculosis multidrug-resistant tuberculosis adverse events |
| title | Efficacy and safety data on pretomanid for drug-resistant TB |
| title_full | Efficacy and safety data on pretomanid for drug-resistant TB |
| title_fullStr | Efficacy and safety data on pretomanid for drug-resistant TB |
| title_full_unstemmed | Efficacy and safety data on pretomanid for drug-resistant TB |
| title_short | Efficacy and safety data on pretomanid for drug-resistant TB |
| title_sort | efficacy and safety data on pretomanid for drug resistant tb |
| topic | tuberculosis extensively drug-resistant tuberculosis pre-extensively drug-resistant tuberculosis multidrug-resistant tuberculosis adverse events |
| url | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2025/00000002/00000002/art00004 |
| work_keys_str_mv | AT httthuy efficacyandsafetydataonpretomanidfordrugresistanttb AT cpadmapriyadarsini efficacyandsafetydataonpretomanidfordrugresistanttb AT cchuchottaworn efficacyandsafetydataonpretomanidfordrugresistanttb AT sforaida efficacyandsafetydataonpretomanidfordrugresistanttb AT shadigal efficacyandsafetydataonpretomanidfordrugresistanttb AT arbirajdar efficacyandsafetydataonpretomanidfordrugresistanttb |